The oncogenic role of HBXIP - 19/12/20
páginas | 9 |
Iconografías | 5 |
Vídeos | 0 |
Otros | 0 |
Abstract |
Hepatitis B X-interacting protein (HBXIP) is a conserved protein of 19 kDa that was originally identified as a binding partner of hepatitis B virus X protein. Emerging evidence indicates that HBXIP is highly expressed in a variety of cancers and is correlated with poor clinical outcomes in cancer patients. HBXIP plays a critical role in cancer progression, but the underlying mechanisms are still unclear. In this review, we primarily focus on publications investigating HBXIP in cancer research, including its expression and clinical significance in cancer patients, its role as a coactivator of transcription factors in cancer cells, its inhibitory effects on the mitochondrial cytochrome c-caspase apoptotic pathway, as well as its roles in promoting mitosis and drug resistance in cancer cells, its regulatory effects on cancer metabolism, and its relationships with other signaling pathways or microRNAs in cancer. This review aims to compile and summarize existing knowledge of the functions of HBXIP in cancer, which provides a comprehensive reference for future studies on the oncogenic mechanisms of HBXIP.
El texto completo de este artículo está disponible en PDF.Abbreviations : Cdc42, Apaf1, PIN1, ERK, KEAP1, ATM, ATR, HOXB13, STAT4, NF-κB, HIF1α, ROS, PI3K, Akt, PDGFB, IL-8, MST1, STAT3, PTEN, S100A4, VEGF, Capn4
Keywords : HBXIP, Oncogenic, Cancer
Esquema
Vol 133
Artículo 111045- janvier 2021 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?